Literature DB >> 16300476

Phosphodiesterase-4 as a potential drug target.

Kam Y J Zhang1, Prabha N Ibrahim, Sam Gillette, Gideon Bollag.   

Abstract

Phosphodiesterase-4 (PDE4) is the predominant enzyme in some specific cell types that is responsible for the degradation of the second messenger, cAMP. Consequently, PDE4 plays a crucial role in cell signalling and, as such, it has been the target of clinical drug development of various indications, ranging from anti-inflammation to memory enhancement. In this review, the fundamental biological role of PDE4 in intracellular signalling, its tissue distribution and regulation are described. The historical development of various chemical classes of PDE4 inhibitors and the challenges that face these inhibitors as therapeutics are also discussed. Finally, recent advances in the structural biology of PDE4 and their complexes with various inhibitors, as well as its potential impact on the rational design of potent and selective PDE4 inhibitors, are presented.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16300476     DOI: 10.1517/14728222.9.6.1283

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  19 in total

1.  Characterization of a catalytic ligand bridging metal ions in phosphodiesterases 4 and 5 by molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations.

Authors:  Ying Xiong; Hai-Ting Lu; Yongjian Li; Guang-Fu Yang; Chang-Guo Zhan
Journal:  Biophys J       Date:  2006-09-01       Impact factor: 4.033

2.  Anchored PDE4 regulates chloride conductance in wild-type and ΔF508-CFTR human airway epithelia.

Authors:  Elise Blanchard; Lorna Zlock; Anna Lao; Delphine Mika; Wan Namkung; Moses Xie; Colleen Scheitrum; Dieter C Gruenert; Alan S Verkman; Walter E Finkbeiner; Marco Conti; Wito Richter
Journal:  FASEB J       Date:  2013-11-07       Impact factor: 5.191

3.  Early alcohol exposure disrupts visual cortex plasticity in mice.

Authors:  Crystal L Lantz; Weili Wang; Alexandre E Medina
Journal:  Int J Dev Neurosci       Date:  2012-05-14       Impact factor: 2.457

4.  Insight into the phosphodiesterase mechanism from combined QM/MM free energy simulations.

Authors:  Kin-Yiu Wong; Jiali Gao
Journal:  FEBS J       Date:  2011-06-14       Impact factor: 5.542

5.  Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme.

Authors:  Judith A Siuciak; Sheryl A McCarthy; Douglas S Chapin; Ashley N Martin
Journal:  Psychopharmacology (Berl)       Date:  2007-12-01       Impact factor: 4.530

Review 6.  Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.

Authors:  Katharine H Banner; Neil J Press
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

Review 7.  The pilot phase of the NIH Chemical Genomics Center.

Authors:  Craig J Thomas; Douglas S Auld; Ruili Huang; Wenwei Huang; Ajit Jadhav; Ronald L Johnson; William Leister; David J Maloney; Juan J Marugan; Sam Michael; Anton Simeonov; Noel Southall; Menghang Xia; Wei Zheng; James Inglese; Christopher P Austin
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

8.  Identification of a potent new chemotype for the selective inhibition of PDE4.

Authors:  Amanda P Skoumbourdis; Ruili Huang; Noel Southall; William Leister; Vicky Guo; Ming-Hsuang Cho; James Inglese; Marshall Nirenberg; Christopher P Austin; Menghang Xia; Craig J Thomas
Journal:  Bioorg Med Chem Lett       Date:  2008-01-11       Impact factor: 2.823

9.  Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.

Authors:  Amanda P Skoumbourdis; Christopher A Leclair; Eduard Stefan; Adrian G Turjanski; William Maguire; Steven A Titus; Ruili Huang; Douglas S Auld; James Inglese; Christopher P Austin; Stephen W Michnick; Menghang Xia; Craig J Thomas
Journal:  Bioorg Med Chem Lett       Date:  2009-01-23       Impact factor: 2.823

10.  Inhibition of cAMP-phosphodiesterase 4 (PDE4) potentiates the anesthetic effects of Isoflurane in mice.

Authors:  Ileana V Aragon; Abigail Boyd; Lina Abou Saleh; Justin Rich; Will McDonough; Anna Koloteva; Wito Richter
Journal:  Biochem Pharmacol       Date:  2021-02-18       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.